Review
doi: 10.1586/erv.09.139.
Domain III of the envelope protein as a dengue vaccine target
Affiliations
- PMID: 20109025
- DOI: 10.1586/erv.09.139
Item in Clipboard
Review
Domain III of the envelope protein as a dengue vaccine target
Expert Rev Vaccines.
2010 Feb.
Free article
Abstract
A dengue vaccine should induce long-lasting, simultaneous protection to the four dengue viruses while avoiding the immune enhancement of viral infection. Domain III of the dengue envelope protein has been implicated in receptor binding, and is also the target of specific neutralizing antibodies. Domain III has emerged as a promising region for a subunit vaccine candidate. Here, we review the current state of knowledge on vaccine candidates based on domain III. Due to the results obtained concerning the immune response and protection in mice and monkeys, particular attention is paid to the chimeric protein domain III fused to p64k of Neisseria meningitidis.
Similar articles
-
Immunogenicity and protective efficacy of a recombinant fusion protein containing the domain III of the dengue 1 envelope protein in non-human primates.Antiviral Res. 2008 Nov;80(2):194-9. doi: 10.1016/j.antiviral.2008.06.005. Epub 2008 Jul 3. Antiviral Res. 2008. PMID: 18602424
-
A tetravalent dengue vaccine containing a mix of domain III-P64k and domain III-capsid proteins induces a protective response in mice.Arch Virol. 2014 Oct;159(10):2597-604. doi: 10.1007/s00705-014-2115-2. Epub 2014 May 20. Arch Virol. 2014. PMID: 24841761
-
An envelope domain III-based chimeric antigen produced in Pichia pastoris elicits neutralizing antibodies against all four dengue virus serotypes.Am J Trop Med Hyg. 2008 Sep;79(3):353-63. Am J Trop Med Hyg. 2008. PMID: 18784226
-
Recent progress in dengue vaccine research and development.Curr Opin Mol Ther. 2010 Feb;12(1):31-8. Curr Opin Mol Ther. 2010. PMID: 20140814 Review.
-
Towards a dengue vaccine: progress to date and remaining challenges.Comp Immunol Microbiol Infect Dis. 2008 Mar;31(2-3):239-52. doi: 10.1016/j.cimid.2007.07.011. Epub 2007 Sep 21. Comp Immunol Microbiol Infect Dis. 2008. PMID: 17889365 Review.
Cited by
-
Exposure to Dengue Envelope Protein Domain III Induces Nlrp3 Inflammasome-Dependent Endothelial Dysfunction and Hemorrhage in Mice.Front Immunol. 2021 Feb 25;12:617251. doi: 10.3389/fimmu.2021.617251. eCollection 2021. Front Immunol. 2021. PMID: 33717109 Free PMC article.
-
Cross-reactivities between human IgMs and the four serotypes of dengue virus as probed with artificial homodimers of domain-III from the envelope proteins.BMC Infect Dis. 2013 Jul 1;13:302. doi: 10.1186/1471-2334-13-302. BMC Infect Dis. 2013. PMID: 23815496 Free PMC article.
-
Dengue Fever: Causes, Complications, and Vaccine Strategies.J Immunol Res. 2016;2016:6803098. doi: 10.1155/2016/6803098. Epub 2016 Jul 20. J Immunol Res. 2016. PMID: 27525287 Free PMC article. Review.
-
Production and immunogenicity of Fubc subunit protein redesigned from DENV envelope protein.Appl Microbiol Biotechnol. 2020 May;104(10):4333-4344. doi: 10.1007/s00253-020-10541-y. Epub 2020 Mar 30. Appl Microbiol Biotechnol. 2020. PMID: 32232529 Free PMC article.
-
Dengue Virus Infection of Aedes aegypti Requires a Putative Cysteine Rich Venom Protein.PLoS Pathog. 2015 Oct 22;11(10):e1005202. doi: 10.1371/journal.ppat.1005202. eCollection 2015 Oct. PLoS Pathog. 2015. PMID: 26491875 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
